63 related articles for article (PubMed ID: 31582531)
21. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
Reddy V; Iskander A; Hwang C; Divine G; Menon M; Barrack ER; Reddy GP; Kim SH
PLoS One; 2019; 14(5):e0211090. PubMed ID: 31083651
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
23. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
Stice JP; Wardell SE; Norris JD; Yllanes AP; Alley HM; Haney VO; White HS; Safi R; Winter PS; Cocce KJ; Kishton RJ; Lawrence SA; Strum JC; McDonnell DP
Mol Cancer Res; 2017 Jun; 15(6):660-669. PubMed ID: 28209757
[TBL] [Abstract][Full Text] [Related]
25. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
[TBL] [Abstract][Full Text] [Related]
26. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
27. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
Cheung FY
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
[TBL] [Abstract][Full Text] [Related]
28. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
[TBL] [Abstract][Full Text] [Related]
29. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
30. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules.
Masoodi KZ; Xu Y; Dar JA; Eisermann K; Pascal LE; Parrinello E; Ai J; Johnston PA; Nelson JB; Wipf P; Wang Z
Mol Cancer Ther; 2017 Oct; 16(10):2120-2129. PubMed ID: 28655783
[TBL] [Abstract][Full Text] [Related]
32. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
33. Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
De Velasco MA; Kura Y; Sakai K; Hatanaka Y; Davies BR; Campbell H; Klein S; Kim Y; MacLeod AR; Sugimoto K; Yoshikawa K; Nishio K; Uemura H
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484823
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
35. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
[TBL] [Abstract][Full Text] [Related]
36. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Holder SL; Abdulkadir SA
Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
[TBL] [Abstract][Full Text] [Related]
37. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
38. Acetyl-l-Carnitine and New-Onset Psychosis During the COVID-19 Pandemic.
Dhir S; Khalid Z; Salcedo J; Shanbour A
Prim Care Companion CNS Disord; 2020 Dec; 22(6):. PubMed ID: 33271642
[No Abstract] [Full Text] [Related]
39. [Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
Matsuura K; Osaki A; Ichinose Y; Fujimoto A; Nukui A; Saeki T
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1605-1608. PubMed ID: 33268737
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive treatment for multicentric giant cell tumors of the pelvis and spine using apatinib: A case report and literature review.
Li J; Zhou J; Liu Y; Sun X; Song W
J Cancer Res Ther; 2020 Sep; 16(5):1020-1026. PubMed ID: 33004743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
